| abstract |
The present invention relates to chimeric monoclonal antibodies, humanized or human that are produced in cell lines selected, said antibodies having a strong affinity for immune system effector cell CD 16 receptor and so capable of inducing strong ADCC, but also the property of inducing secretion of cytokines and interleukins, in particular IFN.gamma., which can enhance ADCC activity of effector cells and thus apply to the treatment of cancers and infections by pathogens. |